Patients with low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL are at high risk of atherosclerotic cardiovascular disease events. Treatment guidelines recommend intensive treatment in these patients. Variation in the use of lipid-lowering therapies (LLTs) in these patients in a national sample of cardiology practices is not known.
recommend intensive treatment of patients with primary elevation of low-density lipoprotein cholesterol (LDL-C). This is based on the finding that patients with LDL-C levels ≥190 mg/dL have a high lifetime risk of atherosclerotic cardiovascular disease (ASCVD) events. 3, 4 Recent studies have shown that although the prevalence of genetic mutations associated with familial hypercholesterolemia (FH) is low among patients with LDL-C ≥190 mg/dL, the risk of future ASCVD events remains high in these patients even in the absence of FH-defining mutations. 4 Studies have shown that the risk of coronary heart disease (CHD) is accelerated by 10 to 20 years in men and 20 to 30 years in women with LDL-C levels ≥190 mg/dL. 3 This increased risk can be mitigated by early identification and treatment of these patients. Statin therapy has been shown to significantly lower future risk of ASCVD events in these patients. [5] [6] [7] The 2013 American College of Cardiology/American Heart Association cholesterol treatment guideline, therefore, identified LDL-C ≥190 mg/dL as 1 of the 4 statin benefit groups. 2 In these patients, the guidelines recommend consideration for early initiation of high-intensity statin therapy. 2, 8 Nonstatin lipid-lowering therapies (LLTs), including ezetimibe and PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, have also been shown to lower LDL-C levels in these patients. 9, 10 Recent studies have shown large treatment gaps in the care of patients with LDL-C ≥190 mg/dL. [11] [12] [13] These studies were performed either outside the United States 12 or included patients seeking care in specialty lipid clinics within the United States. 11 In addition, the use of nonstatin lipid-lowering medications (eg, ezetimibe or PCSK9 inhibitors) in these patients has not been formally evaluated. Another aspect of quality in the care of patients with LDL-C ≥190 mg/dL is to ensure that the prescription of evidence-based lipid-lowering medications does not vary based on where a patient is receiving care (ie, care for this high-risk group should be uniform). To our knowledge, no study has evaluated the use of evidence-based LLTs among these patients seeking care in a nationally representative sample of cardiology practices in the United States. Similarly, practice-level variation in the care of these patients is not known. Using data from the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence (PINNACLE) Registry, we assessed the frequency and practice-level variation in the use of evidence-based LLTs among patients with LDL-C ≥190 mg/dL seeking care in cardiology practices across the United States.
METHODS

Cohort Development
The data, methods used in the analysis, and materials used to conduct the research will not be made available to any researcher for purposes of reproducing the results or replicating the procedure. We utilized data from the National Cardiovascular Data Registry-PINNACLE registry. PINNACLE is the first and the largest prospective US-based outpatient cardiac quality improvement registry with voluntary participation from both academic and nonacademic practices (predominantly cardiology practices) throughout the United States. 14, 15 Data in the registry are directly extracted using algorithms mapped to data in the electronic health records. Quality control is ensured using a standard data collection tool with written definitions, uniform data entry and transmission requirements, and data quality checks. 15, 16 
Study Population
For the current analyses, we first identified patients seeking outpatient cardiology care in the PINNACLE registry from January 1, 2013, to December 31, 2016, with available LDL-C levels (n=2 463 535). Among these patients, we identified 49 447 patients with any LDL-C ≥190 mg/dL, which represents the 98th percentile among all available LDL-C levels in the PINNACLE registry. These 49 447 patients were seeking care in 476 practices across the United States.
WHAT IS KNOWN
• Patients with low-density lipoprotein cholesterol ≥190 mg/dL are at a high long-term risk of atherosclerotic cardiovascular disease events. Treatment guidelines recommend consideration for early initiation of high-intensity statin therapy in these patients.
WHAT THE STUDY ADDS
• This study shows that the use of evidence-based therapies remains low among patients with elevated low-density lipoprotein cholesterol, with only 58.5% of these patients on a statin and 31.9% on high-intensity statin therapy.
• This study also shows that there is a significant practice-level variation in the proportion of patients with low-density lipoprotein cholesterol ≥190 mg/dL receiving statin and high-intensity statin therapy, with a >200% variation in the receipt of high-intensity statin therapy among 2 identical patients receiving care at 2 random practices participating in the Practice Innovation and Clinical Excellence (PINNACLE) registry.
• Practice-level rates for use of nonstatin therapies were also low, with significant practice-level variation in the use of ezetimibe and PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors among these patients.
• These results indicate that system-level interventions are needed to address these treatment gaps and to reduce variation in care of these patients.
Because we wanted to assess both no treatment and undertreatment of these patients, we evaluated the use of statin therapy, high-intensity statin therapy, LLT associated with ≥50% LDL-C reduction, ezetimibe therapy, or PCSK9 inhibitors (alirocumab or evolocumab) among patients with LDL-C ≥190 mg/dL. High-intensity statin therapy was defined per the 2013 American College of Cardiology/American Heart Association cholesterol guideline 2 as the use of statin therapy which would on average lower LDL-C levels by ≥ 50%. Given that prior studies show that the use of LDL-C lowering ≥50% serves as a good indicator of future ASCVD outcomes among treated patients 17 and can be used as an indicator of quality of care in patients with elevated LDL-C, 12 we also evaluated any combination of LLT that would be associated with at least a 50% LDL-C reduction as described in a previous study. 12 These included the use of a high-intensity statin (with or without ezetimibe or a PCSK9 inhibitor), use of a moderate-intensity statin plus ezetimibe, or the use of a PCSK9 inhibitor with or without a statin or ezetimibe. Because patients could have multiple outpatient cardiology visits during the study interval, documentation of the use of an LLT (statin, ezetimibe, or PCSK9 inhibitor) at any encounter was taken as evidence of the use of these medications. To further account for dosedependent statin intolerance, we used the highest documented intensity of statin therapy at any encounter during the study interval to calculate the intensity of statin therapy.
Study Outcomes and Analyses
We first assessed the proportion of patients with LDL-C ≥190 mg/dL on statin therapy and on high-intensity statin therapy. We also assessed the proportion of these patients receiving LLT associated with ≥50% LDL-C reduction, ezetimibe, or a PCSK9 inhibitor.
We compared several baseline characteristics among patients receiving statin therapy and those not receiving statin therapy using the χ 2 statistic or Student t test for categorical and continuous variables, respectively. Similar analyses were performed to compare patients receiving high-intensity statin versus those not receiving high-intensity statin therapy. Baseline characteristics included patient's age, sex, race, insurance type, history of hypertension, diabetes mellitus, current smoking, coronary artery disease (CAD), myocardial infarction, percutaneous coronary intervention, peripheral artery disease (PAD), stroke, or transient ischemic attack (TIA).
We then calculated median practice-level rates and interquartile range (IQR) for the use of statin therapy, highintensity statin therapy, LLT associated with ≥50% LDL-C reduction, ezetimibe, or a PCSK9 inhibitor. To calculate this, the number of patients on each of these therapies in a practice was used as the numerator and the total number of patients with LDL-C ≥190 mg/dL in a practice was used as the denominator. We first examined these rates across practice using descriptive plots. To further examine and quantify the extent of practice-level variation in statin use, we constructed multivariable hierarchical regression models to determine the median rate ratio (MRR), which is a well-described measure to assess variation in care. 14, [18] [19] [20] These were 2-level hierarchical models to adjust for clustering of patients within practices, with the individual practices modeled as a random effect and patient characteristics as filter effects within each practice. 21 This approach allowed us to control for measured confounding between practices because the use of hierarchical models ensured that patients with similar baseline characteristics were compared with each other. We first calculated unadjusted MRR. We then adjusted for patient characteristics (age, sex, insurance status [private versus public versus others], history of hypertension, diabetes mellitus, current smoking, history of CAD, stroke, or PAD) followed by adjustment for practice-level variables (geographical location of the practice where the patient is seeking care and the number of years that the practice has been participating in the PINNACLE registry) to assess whether there was any attenuation in MRRs after these adjustments. The calculated MRR can be interpreted as the likelihood that 2 random practices would differ in treatment of identical patients. For example, an MRR of 1 suggests no practice-level variation and similar treatment at 2 random practices for identical patients with LDL-C ≥190 mg/dL, whereas an MRR of 1.50 suggests 50% probability of differing treatment for identical patients with LDL-C ≥190 mg/dL between 2 random practices. Based on prior studies, MRRs of >1.20 are generally considered to indicate significant practice-level variation.
14,18-20 Similar analyses were performed for high-intensity statin use, use of LLT associated with ≥50% LDL-C reduction, ezetimibe use, and PCSK9 inhibitor use.
We also performed several sensitivity analyses. These included evaluating the proportion of patients aged <50 years with LDL-C ≥190 mg/dL who were on a statin, high-intensity statin, LLT associated with ≥50% LDL-C reduction, ezetimibe, and PCSK9 inhibitor. We also evaluated these results after excluding patients with LDL-C ≥190 mg/dL with concomitant ASCVD (history of CAD, PAD, stroke, or TIA). Analyses were performed using SAS, version 9.3 (SAS Institute, Cary, NC). All P values described are 2 sided. A P value <0.05 was considered significant. The protocol was approved by the Institutional Review Boards at Baylor College of Medicine and the Michael E. DeBakey VA Medical Center.
RESULTS
Our final study cohort included 49 447 patients with LDL-C levels ≥190 mg/dL. The distribution of LDL-C levels in these patients was right skewed (Figure 1 ) with mean (SD) and median (IQR) LDL-C levels of 214 (24.5) and 205 (196-222) mg/dL, respectively. The number (%) of patients with LDL-C levels between 190 to 219 mg/dL, 220 to 249 mg/dL, 250 to 279 mg/dL, 280 to 309 mg/dL, and ≥310 mg/dL were 35 699 (72.2%), 9243 (18.7%), 2689 (5.4%), 1053 (2.1%), and 763 (1.5%), respectively; 11.8% of the patients were receiving care in practices located in the West region, 20.8% in practices located in the Midwest, 16.75% in practices located in the Northeast, and 50.65% in practices located in the South.
In this cohort of 49 447 patients, the number of patients (percentage) receiving statin therapy, highintensity statin therapy, LLT associated with ≥50% LDL-C reduction, ezetimibe, or a PCSK9 inhibitor were 28 950 (58.5%), 15 791 (31.9%), 17 094 (34.6%), 4194 (8.5%), and 732 (1.5%), respectively. Patients receiving statin therapy compared with those not receiving statins (Table 1) were slightly younger, more likely to be men, current smokers, more likely to be receiving care in practices in the West region, and less likely to be white or receiving care in practices in South region. Patients receiving statins also had a higher prevalence of CAD, diabetes mellitus, hypertension, chronic kidney disease, myocardial infarction, percutaneous coronary intervention, stroke, or TIA compared with those not receiving statin therapy. Patients receiving statins had minimally higher LDL-C levels (215 mg/dL) compared with those not receiving statin therapy (212 mg/dL) and were also more likely to receive ezetimibe or either alirocumab or evolocumab. Qualitatively similar results were seen when comparing patients receiving high-intensity statin therapy versus those not receiving high-intensity statin therapy (Table 2) .
Practice-Level Variation in Statin and High-Intensity Statin Therapy Use
Median practice-level rates (IQR) for statin therapy (Table 3 ; Figure 2 ) were 56% (IQR, 47.3%-64.8%). As noted in Figure 2 , there was significant practicelevel variation in the proportion of patients with LDL-C ≥190 mg/dL receiving statin therapy varying from just >10% of patients in some practices to >90% of patients in others. Unadjusted MRR for statin therapy use was 1.24, which was minimally attenuated in a model adjusting for patient-and practice-level variables (adjusted MRR, 1.20; 95% confidence interval [CI], 1.17-1.23).
Median practice-level rate (IQR) for high-intensity statin use was 30.2% (IQR, 12.1%-41.1%; Table 3 ; Figure 2) . There was substantial practice-level variation in high-intensity statin therapy use with several practices having <10% of patients on high-intensity statin therapy and a few practices having >50% of patients on highintensity statin therapy. There was substantial practicelevel variation in the use of high-intensity statin therapy (unadjusted MRR, 2.51; 95% CI, 2.29-2.73), which was modestly attenuated after adjusting for patient-and practice-level characteristics (adjusted MRR, 2.31; 95% CI, 2.12-2.51). These results indicate large practice-level variation in high-intensity statin therapy use between 2 similar patients with LDL-C ≥190 mg/dL treated at 2 random practices with 1 patient 131% more likely to receive a high-intensity statin compared with another patient with similar characteristics.
Practice-Level Variation in the Use of LLT Associated With ≥50% LDL-C Reduction
Median practice-level rate for the use of LLT associated with ≥50% LDL-C reduction (Table 3; Figure 2 ) was 31.8% (IQR, 15.3%-45.5%). There was substantial practice-level variation. The fully adjusted MRR across practices was 2.12 (95% CI, 1.95-2.28). History of hypertension, diabetes mellitus, current smoking, CAD, ischemic stroke, or PAD was associated with a higher likelihood of receiving LLT associated with ≥50% LDL-C reduction. Increasing age of the patient, female sex, and location of the practice in the Midwest or South (compared with the West region) were associated with a lower likelihood of receiving LLT associ- ated with ≥50% LDL-C reduction (Table I in the Data Supplement). Patient's type of insurance or the number of years of participation by the practice in PINNACLE registry were not significantly associated with receipt of LLT regimen associated with ≥50% LDL-C reduction.
Practice-Level Variation in the Use of Nonstatin Therapies
Median (IQR) practice-level rates for ezetimibe and PCSK9 inhibitor use were 5.8% (2.8%-9.8%) and 0.16% (0%-1.9%), respectively. As noted (Table 3 ; Figure 2 ), there was significant practice-level variation in the use of ezetimibe and PCSK9 inhibitors among these patients, with minimal impact of patient-and practice-level characteristics ( 
Sensitivity Analyses
Among patients <50 years of age with LDL-C ≥190 mg/ dL (n=7456), the proportions on a statin, high-intensity statin, LLT regimen associated with ≥50% LDL-C reduction, ezetimibe, and PCSK9 inhibitor were 58.1%, 31.6%, 33.4%, 4.96%, and 1.08%, respectively.
Among patients (n=21 091) without any history of CAD, PAD, stroke, or TIA, the use of LLTs was even lower (proportion of patients on a statin, high-intensity statin, lipid-lowering regimen associated with ≥50% LDL-C reduction, ezetimibe, or PCSK9 inhibitor were 50.8%, 25.25%, 26.8%, 4.9%, and 0.74%, respectively).
We also evaluated quarterly time trends in the use of ezetimibe or PCSK9 inhibitors in our study cohort (Figures I and II in the Data Supplement). As seen, the rates for the use of ezetimibe in our study cohort gradually increased throughout the study interval but have plateaued around 10% to 11% since the last quarter of 2015. For PCSK9 inhibitors, there was a steady increase in their use from the third quarter of 2015 (0.34%) to their highest level in the second quarter of 2016 (3.39% of the patients) but have since stabilized.
DISCUSSION
In these analyses from a national registry of outpatients receiving care in cardiology practices across the United States, we found that roughly 4 in 10 patients with LDL-C ≥190 mg/dL were not on statin therapy and less than one third were on high-intensity statin therapy. Our results also show a 20% and 131% variation in the use of statin and high-intensity statin therapy among 2 similar patients with LDL-C ≥190 mg/dL receiving care at 2 random practices. Despite their high LDL-C levels, the use of nonstatin therapies (ezetimibe or PCSK9 inhibitors) was low. Although treatment guidelines recommend at least a 50% reduction in LDL-C levels as the first step in these high-risk patients, 2 only 35% of the patients were on a lipid-lowering regimen, which would lead to at least a 50% LDL-C reduction. These results indicate that a lack of treatment, under treatment, and substantial variation in care independent of patient characteristics are common among these patients.
Our results are broadly consistent with results shown in a registry of 1295 adults with heterozygous FH from 11 lipid clinics in the United States. 11 In that study, roughly 25% were not receiving statin therapy, and 42% were receiving high-intensity statin therapy. Only 41% of the patients achieved ≥50% LDL-C reduction. The lower number of patients on statin or high-intensity statin therapy in our study compared with this study can be explained by differences in practices enrolled in the study (specialized lipid clinics versus general cardiology practices). To our knowledge, this is the first study evaluating the quality of cholesterol care in this high-risk patient population among a national sample of cardiology practices. Similar results have also been described in a registry of 4132 patients in Spain. 12 Studies have shown that patients with LDL-C ≥190 mg/dL (even in the absence of FH-defining mutations) have a high lifetime risk of ASCVD. 3, 4 In the Cardiovascular Lifetime Risk Pooling Project, individuals with LDL-C ≥190 mg/dL had ≤5× higher risk of CHD at 30 years of follow-up compared with those with LDL-C <130 mg/ dL. 3 It is important to note that although relative risk was higher with higher LDL-C levels in younger individuals, the absolute risk still remains low because of low event rates when compared with those with established ASCVD. 22 Conversely, CHD risk was accelerated by 10 to 20 years in men and 20 to 30 years in women with LDL-C ≥190 mg/dL, and, therefore, elevated LDL-C levels in this population represent a modifiable risk factor. For example, the event rate of 2.6 events (CHD death or nonfatal myocardial infarction) per 1000 person-years of follow-up among 20-to 29-year-old men was comparable with an event rate of 1.5 per 1000 person-years of follow-up among men 30 to 39 years of age with LDL-C <130 mg/dL and 4.0 events per 1000 personyears of follow-up among 40-to 49-year-old men with LDL-C <130 mg/dL. Similarly, although the risk of CHD has been described as 22-fold higher among patients with FH-defining mutations (likely because of high lifetime exposure to elevated LDL-C levels), the future risk of CHD remains 6-fold higher among those with LDL-C ≥190 mg/dL and no FH-related mutations. 4 Recent studies have also shown that as opposed to prevalence of heterozygous FH of 1 in 250, prevalence of LDL-C ≥190 mg/dL may be as high as 5% to 7% in the general population, and, therefore, the population-attributable risk associated with this phenotype (and its undertreatment) is high. 3, 13 Although the exact reasons for the undertreatment of these high-risk patients (treatment-risk paradox) are not well known, our prior national surveys might explain some reasons for clinical inertia 23, 24 in the treatment of these patients. 25, 26 These national surveys, which included both cardiologists and internal medicine providers, showed that 52% of the providers would not perform a risk discussion on possible initiation of statin therapy in patients with LDL-C ≥190 mg/dL but would rather continue with lifestyle modification alone, perform a 10-year ASCVD risk estimation, perform a coronary calcium score or carotid intima-media thickness, or reassure the patient and repeat cholesterol levels in 5 years. In the same survey, only 29% of the providers knew the definition of low-, moderate-, and high-intensity statin therapy. 25 These results indicate that providers may not think of patients with LDL-C ≥190 mg/dL as high risk. In addition to explaining why such a large CAD indicates coronary artery disease; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; and PCI, percutaneous coronary intervention.
proportion of these patients are not on statin therapy, it may also explain why the intensity of LLT is low in these patients. These gaps at the level of individual providers may also explain why there is a significant residual variation in care even after adjustments are made for a large number of patient-and practice-level variables. It is important to note that patients referred to cardiology practices are inherently at high risk because of referral bias because these patients are already deemed to have signs and symptoms suggestive of ASCVD. This is evident from the fact that roughly 40% of the patients in our cohort already had concomitant CAD, 8% had PAD, 10% to 15% had history of stroke or TIA, and 21% had diabetes mellitus, which would make use of statin and moderate-to high-intensity statin therapy a class I indication even without elevated LDL-C levels. In the absence of these comorbid conditions, treatment gaps are even worse, as shown in our sensitivity analyses. A much larger treatment gap and a more significant magnitude of practice-level variation for the use of highintensity statin therapy, LLT with ≥50% LDL-C reduction, and nonstatins compared with statin use indicates that although clinicians may agree on the need for LLT in these patients, the intensity of therapy that is used is not uniform. Last, some patients with LDL-C ≥190 mg/dL could also not perceive themselves as high risk. These patient perceptions may not be well accounted for by variables used in our adjustment model.
Our results also show significant practice-level variation in the use of statin, high-intensity statin therapy, LLT associated with ≥50% LDL-C reduction, and nonstatin therapy use among these patients. These results indicate that there is heterogeneity among practices in the treatment of patients with LDL-C ≥190 mg/dL with some practices more successful in treating these patients with evidence-based medications. Differences in patient-related factors (or tolerance to statin therapy) across practices could also account for some of these differences. Attenuation of some practice-level variation after adjustment for patient characteristics but persistence of significant practice-level variation indicates that efforts to address these gaps should target both clinicians and patients.
What can be done to address these gaps and reduce variation in the care of this high-risk group? An Institute of Medicine report noted that it takes 17 years for knowledge to be implemented in routine clinical practice. 27 This time lag between generation of knowledge and its implementation in routine clinical practice is unacceptable. Prior studies have shown that passive diffusion of knowledge via guideline publication may not suffice. These efforts will need to be supplemented with active interventions like audit and feedback to the providers on quality of care that is delivered to these high-risk patients 28 and patient-centered interventions, such as mutual goal setting. These tools should provide cognitive support to providers at the point-of-care to first identify these high-risk patients, prompt them to perform high-quality risk discussion to help patients understand the importance of treating such high LDL-C levels, tools to initiate evidence-based LLTs, and tools to encourage providers to perform lipid testing on other first-degree relatives of the identified patients. This must be done with careful review of existing workflows, garnering participation and buy-in by the clinical users, and using human factors best practices, as clinicians are notably overburdened with information, and studies have shown clinical reminder burnout that results in ignoring the decision support. 29, 30 Several recent initiatives by the FH foundation (creation of the CASCADE-HF [Cascade Screening for Awareness and Detection of Familial Hypercholesterolemia] Registry, 11 deployment of advanced informatics to identify patients with FH, provider, and patient resources) and the American College of Cardiology National Cardiovascular Data Registry-PINNACLE registry (dashboards for practices on their performance in the use of evidence-based LLTs in patients with LDL-C ≥190 mg/dL) should further assist in improving the care of these high-risk patients.
Our study has limitations. These results represent whether a statin, high-intensity statin, or a nonstatin †Adjusted for patient characteristics plus practice-level characteristics (geographical location of the practice where the patient is seeking care and the number of years that the practice is participating in the PINNACLE registry).
therapy was prescribed to the patient. Given the limitations of data captured in the PINNACLE registry, we are not able to comment on whether patients were adherent to their prescribed medications. We also do not have data on family history of premature ASCVD or family history of elevated LDL-C levels, which would allow us to determine how many of these patients fulfill clinical criteria for FH. Also, given that the patient population in PINNACLE mostly reflects a referred population, baseline pretreatment LDL-Cs are generally not available for the cohort of patients studied. To overcome this issue, we assessed any value of LDL-C during the study interval, as well as the highest intensity of statin therapy noted on any encounter during that time. Of course, this approach will exclude some patients as a function of the intensity of their treatment but will tend to underestimate the degree of undertreatment we report. For nonstatin therapies, especially PCSK9 inhibitors, formulary restrictions and difficulties obtaining prior approval could have contributed to the low number of patients on this therapy. It is possible that the low number of patients prescribed statin therapy could represent patient refusal to accept statin therapy after risk discussion or patient intolerance to statin therapy. Our post hoc analyses show that among those not on a statin, only 152 (0.7%) patients refused a statin as documented by the providers. Although partial or complete statin intolerance could explain some of our results, a large prior registry of 7924 patients showed the prevalence of muscular symptoms to be close to 10.5% in statin-treated patients. 31 Recent studies have also shown that many of these statin-intolerant patients can tolerate some form of statin therapy. 32, 33 Our results (Tables 1 and 2 ) also show that on average, the use of nonstatin therapies was higher among patients receiving statin or high-intensity statin therapy. If statin intolerance was to be responsible for this treatment gap, then the proportion of patients receiving nonstatin therapies (especially ezetimibe because of its easy availability) should have been higher among patients not receiving a statin or a high-intensity statin. Some patients with high LDL-C in our cohort could have a secondary cause of hyperlipidemia that we could not account for, such as severe hypothyroidism, nephrotic syndrome, or cholestasis. Although this is possible, prevalence of these disorders in a population referred to outpatient cardiology practices is likely low with at least some patients with these secondary lipid disorders still requiring LLT. Finally, our results represent quality of care among practices participating in the PINNACLE registry. By participating in a quality improvement registry, these practices are likely different compared with other cardiology practices and, therefore, treatment gaps could be worse in average cardiology practices across the United States. 
Conclusions
Significant treatment gaps persist in evidence-based LLT use among patients with elevated LDL-C levels in a national sample of cardiology practices. Similarly, there is a significant practice-level variation in the use of evidence-based LLTs in these patients. System-level interventions are needed to address these gaps and to reduce variation in care for this high-risk group.
